Revenue from Contract with Customer, Excluding Assessed Tax of Nabriva Therapeutics plc from 31 Dec 2016 to 30 Jun 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Nabriva Therapeutics plc quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 31 Dec 2016 to 30 Jun 2023.
  • Nabriva Therapeutics plc Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 30 Jun 2023 was $2,243,000, a 76% decline year-over-year.
  • Nabriva Therapeutics plc Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending 30 Jun 2023 was $29,557,000, a 16% decline year-over-year.
  • Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $36,935,000, a 28% increase from 2021.
  • Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $28,895,000, a 475% increase from 2020.
  • Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2020 was $5,027,000, a 47% decline from 2019.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

Nabriva Therapeutics plc Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $29,557,000 $2,243,000 -$6,948,000 -76% 01 Apr 2023 30 Jun 2023 10-Q 19 Oct 2023 2023 Q2
Q1 2023 $36,505,000 $7,590,000 -$430,000 -5.4% 01 Jan 2023 31 Mar 2023 10-Q 22 May 2023 2023 Q1
Q4 2022 $36,935,000 $10,571,000 +$1,310,000 +14% 01 Oct 2022 31 Dec 2022 10-K 17 Apr 2023 2022 FY
Q3 2022 $35,625,000 $9,153,000 +$291,000 +3.3% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $35,334,000 $9,191,000 +$948,000 +12% 01 Apr 2022 30 Jun 2022 10-Q 19 Oct 2023 2023 Q2
Q1 2022 $34,386,000 $8,020,000 +$5,491,000 +217% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023 2023 Q1
Q4 2021 $28,895,000 $9,261,000 +$6,801,000 +276% 01 Oct 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
Q3 2021 $22,094,000 $8,862,000 +$7,571,000 +586% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $14,523,000 $8,243,000 +$7,756,000 +1593% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $6,767,000 $2,529,000 +$1,740,000 +221% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $5,027,000 $2,460,000 +$2,127,000 +639% 01 Oct 2020 31 Dec 2020 10-K 17 Apr 2023 2022 FY
Q3 2020 $2,900,000 $1,291,000 -$5,629,000 -81% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $8,529,000 $487,000 -$38,000 -7.2% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $8,567,000 $789,000 -$914,000 -54% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $9,481,000 $333,000 -$464,000 -58% 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2020 2019 FY
Q3 2019 $9,945,000 $6,920,000 +$6,459,000 +1401% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $3,486,000 $525,000 -$322,000 -38% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $3,808,000 $1,703,000 -$5,848,000 -77% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $9,656,000 $797,000 -$325,000 -29% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $9,981,000 $461,000 -$1,007,000 -69% 01 Jul 2018 30 Sep 2018 10-K 12 Mar 2020 2019 FY
Q2 2018 $10,988,000 $847,000 -$204,000 -19% 01 Apr 2018 30 Jun 2018 10-K 12 Mar 2020 2019 FY
Q1 2018 $11,192,000 $7,551,000 +$5,873,000 +350% 01 Jan 2018 31 Mar 2018 10-K 12 Mar 2020 2019 FY
Q4 2017 $5,319,000 $1,122,000 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
Q3 2017 $1,468,000 01 Jul 2017 30 Sep 2017 10-K 12 Mar 2019 2018 FY
Q2 2017 $1,051,000 01 Apr 2017 30 Jun 2017 10-K 12 Mar 2019 2018 FY
Q1 2017 $1,678,000 01 Jan 2017 31 Mar 2017 10-K 12 Mar 2019 2018 FY

Nabriva Therapeutics plc Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $36,935,000 +$8,040,000 +28% 01 Jan 2022 31 Dec 2022 10-K 17 Apr 2023 2022 FY
2021 $28,895,000 +$23,868,000 +475% 01 Jan 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
2020 $5,027,000 -$4,454,000 -47% 01 Jan 2020 31 Dec 2020 10-K 17 Apr 2023 2022 FY
2019 $9,481,000 -$175,000 -1.8% 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2022 2021 FY
2018 $9,656,000 +$4,337,000 +82% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2021 2020 FY
2017 $5,319,000 -$1,163,000 -18% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
2016 $6,482,000 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.